Literature DB >> 11893031

Evaluation of numeric alterations of chromosomes 1 and 17 by in situ hybridization in invasive breast carcinoma with clinicopathologic parameters.

Lydia Nakopoulou1, Ioanna Giannopoulou, Dimitrios Trafalis, Hariklia Gakiopoulou, Antonios Keramopoulos, Panayiotis Davaris.   

Abstract

Breast cancer is a genetically complex disease and is frequently associated with nonrandom chromosomal alterations. The occurrence of aberrations involving chromosomes 1 and 17 in malignant tissues of breast cancer patients has not been studied systematically. The numeric aberrations of chromosomes 1 and 17 were detected by nonisotopic in situ hybridization on paraffin-embedded tissue sections from 44 invasive breast carcinomas (42 cases available for chromosome 17) and were correlated with clinicopathologic parameters, patients' survival, p53, and c-erbB-2 proteins. Chromosome 17 and 1 aneuploidy were observed in the majority of breast carcinomas with equal percentages of polysomy and monosomy for chromosome 17 and predominance of polysomy for chromosome 1. Monosomy of chromosome 17 was significantly associated with positive lymph nodes and negative estrogen receptor (ER) immunohistochemical expression. Patients with chromosome 17 monosomy were at greater risk of death. Ductal carcinoma displayed a greater percentage of chromosome 1 polysomy than lobular ones. A statistically significant association was demonstrated between chromosome 1 polysomy and higher nuclear grade. Patients with chromosome 1 aneuploidy were at greater risk of death, and especially those with ER negativity. Aneuploid patients with c-erbB-2(-)/PR(-) phenotype demonstrated lower survival rates. These data suggest a possible susceptibility of chromosome 17 to losses and gains and chromosome 1 to gains. Chromosome 17 monosomy and chromosome 1 aneuploidy may be useful prognostic markers in breast cancer patients.

Entities:  

Mesh:

Year:  2002        PMID: 11893031     DOI: 10.1097/00129039-200203000-00004

Source DB:  PubMed          Journal:  Appl Immunohistochem Mol Morphol        ISSN: 1533-4058


  7 in total

1.  Prognostic value of TOP2A gene amplification and chromosome 17 polysomy in early breast cancer.

Authors:  Anna Zaczek; Aleksandra Markiewicz; Anna Supernat; Natalia Bednarz-Knoll; Burkhardt Brandt; Barbara Seroczyńska; Jarosław Skokowski; Jolanta Szade; Piotr Czapiewski; Wojciech Biernat; Marzena Wełnicka-Jaśkiewicz; Jacek Jassem
Journal:  Pathol Oncol Res       Date:  2012-03-18       Impact factor: 3.201

2.  Lack of independent prognostic and predictive value of centromere 17 copy number changes in breast cancer patients with known HER2 and TOP2A status.

Authors:  Kirsten Vang Nielsen; Bent Ejlertsen; Susanne Møller; Maj-Britt Jensen; Eva Balslev; Sven Müller; Ann Knoop; Henning T Mouridsen
Journal:  Mol Oncol       Date:  2011-11-26       Impact factor: 6.603

3.  Prognostic value of chromosome 1 and 8 copy number in invasive ductal breast carcinoma among Iranian women: an interphase FISH analysis.

Authors:  Farkhondeh Behjati; Morteza Atri; Hossein Najmabadi; Keramat Nouri; Mahdi Zamani; Parvin Mehdipour
Journal:  Pathol Oncol Res       Date:  2005-09-29       Impact factor: 3.201

4.  Monosomy of chromosome 17 in breast cancer during interpretation of HER2 gene amplification.

Authors:  Matteo Brunelli; Alessia Nottegar; Giuseppe Bogina; Anna Caliò; Luca Cima; Albino Eccher; Caterina Vicentini; Lisa Marcolini; Aldo Scarpa; Serena Pedron; Eleonora Brunello; Sakari Knuutila; Anna Sapino; Caterina Marchiò; Emilio Bria; Annamaria Molino; Luisa Carbognin; Giampaolo Tortora; Bharat Jasani; Keith Miller; Ibrahim Merdol; Lucia Zanatta; Licia Laurino; Tiina Wirtanen; Giuseppe Zamboni; Marcella Marconi; Marco Chilosi; Erminia Manfrin; Guido Martignoni; Franco Bonetti
Journal:  Am J Cancer Res       Date:  2015-06-15       Impact factor: 6.166

5.  HER-2, TOP2A and chromosome 17 alterations in breast cancer.

Authors:  Asli Rehber Beser; Sitki Tuzlali; Deniz Guzey; Semra Dolek Guler; Seniha Hacihanefioglu; Nejat Dalay
Journal:  Pathol Oncol Res       Date:  2007-10-07       Impact factor: 3.201

6.  Impact of polysomy 17 on HER-2/neu immunohistochemistry in breast carcinomas without HER-2/neu gene amplification.

Authors:  Priti Lal; Paulo A Salazar; Marc Ladanyi; Beiyun Chen
Journal:  J Mol Diagn       Date:  2003-08       Impact factor: 5.568

Review 7.  Breast cancer and aneusomy 17: implications for carcinogenesis and therapeutic response.

Authors:  Monica M Reinholz; Amy K Bruzek; Daniel W Visscher; Wilma L Lingle; Matthew J Schroeder; Edith A Perez; Robert B Jenkins
Journal:  Lancet Oncol       Date:  2009-03       Impact factor: 41.316

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.